Clostridioides difficile infections (CDIs) have decreased in the past years, but since 2021,
some hospitals have reported an increase in CDI rates. CDI remains a global concern and …

Oral vancomycin and metronidazole, though they are the therapeutic choice for
Clostridioides difficile infections (CDIs), also markedly disturb microbiota, leading to a …

Clostridioides difficile infection (CDI) has emerged as a major health problem worldwide. A
major risk factor for disease development is prior antibiotic use, which disrupts the normal …

Antibiotics strongly disrupt the human gut microbiota, which in consequence loses its
colonization resistance capacity, allowing infection by opportunistic pathogens such as …

This review summarizes the latest advances in treating and preventing Clostridium difficile
infection (CDI), the most common infectious disease cause of nosocomial diarrhea in adults …

Clostridioides difficile infection poses significant clinical challenges due to its recurrent
nature. Current antibiotic management does not address the underlying issue, that of a …

In the past two years an enormous amount of molecular, genetic, metabolomic and
mechanistic data on the host-bacterium interaction, a healthy gut microbiota and a possible …

Clostridioides difficile is the causative agent of antibiotic-associated diarrhea, a worldwide
public health problem. Different factors can promote the progression of C. difficile infection …

Purpose of review We reviewed seminal papers and recently published articles discussing
multiple aspects of infection prevention applied to Clostridioides (formerly Clostridium) …

The species composition of the human gut microbiota is related to overall health, and a
healthy gut microbiome is crucial in maintaining colonization resistance against pathogens …